AUNP 12
Tocris Bioscience, part of Bio-Techne | Catalog # 7831
Peptide inhibitor of the PD-1 signaling pathway
Key Product Details
Description
Peptide inhibitor of the PD-1 signaling pathway
Product Description
AUNP 12 is an immune checkpoint modulator targeting the programmed cell death 1 (PD-1) signaling pathway. It inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2. In the mouse splenocyte assay system, AUNP 12 rescues proliferation (EC50 values are 17 and 16 nM for PD-L1 and PD-L2, respectively) and enhances T-cell activity by restoring IFNγ release inhibited by PD-L1 and PD-L2 (EC50 values are 49 nM and 51 nM respectively). In a mouse Renca renal cell carcinoma model, AUNP 12 shows an additive antitumor effect when combined with Cyclophosphamide (Cat. No. 4091).Product Specifications
Molecular Weight
3261.56
Formula
C142H226N40O48
Storage
Store at -20°C
Purity
≥95% (HPLC)
CAS Number
1353563-85-5
PubChem ID
154701623
InChI Key
ZBJUUYIGBAQYBN-QKLNNLIKSA-N
SMILES
OC(CC[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H]([C@H](CC)C)NC([C@@H](NC([C@@H](NC([C@H](CCCCN)NC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@@H](NC([C@@]([H])(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CO)N)=O)CC(N)=O)=O)[C@@H](C)O)=O)CO)=O)=O)=O)=O)CCCCNC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)NC([C@H](CO)N)=O)=O)=O)=O)CCC(O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=CC=C4)=O)CCCNC(N)=N)=O)C(C)C)=O)[C@@H](C)O)=O)CCC(N)=O)=O)CC(C)C)=O)C)=O)=O)=O)C)=O)CCC(N)=O)=O)=O)=O)=O
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solubility | Soluble to 2mg/ml in water |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Sasikumar A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy. Mol.Cancer Ther. 2019 PMID: 31015307
- Zhan From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov.Today 2016 PMID: 27094104
- Omstead CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model. Carcinogenesis 2022 PMID: 35552655
Product Specific Notices for AUNP 12
For research use only
Loading...
Loading...